CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CRISPR Therapeutics AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$50.04+0.79 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
CRISPR Therapeutics AG revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue [Member] | $10.00M | $1.00M | $0 | $0 | $0 | $0 | $35.00M | $0 | $0 | $0 | $200.00M | $0 | 98.2% | – |
| Grant Revenue [Member] | $181.00K | $458.00K | $864.00K | $889.00K | $892.00K | $865.00K | $691.00K | $602.00K | $517.00K | $504.00K | $1.21M | $0 | 1.8% | -79.7% |
By region
From the segment and revenue-disaggregation notes of CRISPR Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.